Upstream Bio (UPB) IPO Deck
Upstream Bio focuses on developing monoclonal antibody therapies for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease (COPD).
Upstream Bio focuses on developing monoclonal antibody therapies for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease (COPD).
%20IPO%20Deck){kind=link}